Cytokines as therapeutic targets in primary Sjögren syndrome

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Pharmacology and Therapeutics

• Publication date

  2017-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.pharmthera.2017.10.019PMID 29092775
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Clinical Efficacy and Safety of Baminercept, a Lymphotoxin β Receptor Fusion Protein, in Primary Sjögren's Syndrome

  2018cited by this paper
• Increased expression of interferon-λ in minor salivary glands of patients with primary Sjögren's syndrome and its synergic effect with interferon-α on salivary gland epithelial cells.

  2018cited by this paper
• B Cell Depletion Therapy Normalizes Circulating Follicular Th Cells in Primary Sjögren Syndrome

  2017cited by this paper
• Targeting PI3K Signaling in Combination Cancer Therapy.

  2017cited by this paper
• Clinical relevance of ROR&ggr; positive and negative subsets of CD161+CD4+ T cells in primary Sjögren’s syndrome

  2017cited by this paper
• Elevated IL-37, IL-18 and IL-18BP serum concentrations in patients with primary Sjögren's syndrome

  2017cited by this paper
• Multiomic disease signatures converge to cytotoxic CD8 T cells in primary Sjögren’s syndrome

  2017cited by this paper
• Mechanisms and New Strategies for Primary Sjögren's Syndrome.

  2017cited by this paper
• Identification of a Sjögren's syndrome susceptibility locus at OAS1 that influences isoform switching, protein expression, and responsiveness to type I interferons

  2017cited by this paper
• Reviewing primary Sjögren's syndrome: beyond the dryness - From pathophysiology to diagnosis and treatment

  2017cited by this paper
• TLR2 signals via NF-κB to drive IL-15 production in salivary gland epithelial cells derived from patients with primary Sjögren’s syndrome

  2017cited by this paper
• Genome‐Wide Association Analysis Reveals Genetic Heterogeneity of Sjögren's Syndrome According to Ancestry

  2017cited by this paper
• Pyoderma gangrenosum in Sjögren's syndrome and its successful treatment with topical application of etanercept

  2017cited by this paper
• Efficacy of belimumab and targeting of rheumatoid factor-positive B-cell expansion in Sjögren's syndrome: follow-up after the end of the phase II open-label BELISS study.

  2016influential reference
• Use of Biologics in Sjögren's Syndrome.

  2016cited by this paper
• Interferon-γ-Induced Unfolded Protein Response in Conjunctival Goblet Cells as a Cause of Mucin Deficiency in Sjögren Syndrome.

  2016cited by this paper
• Interleukin-33, friend and foe in type-2 immune responses.

  2016cited by this paper
• Sjögren syndrome

  2016cited by this paper
• Restoring regulation – IL-2 therapy in systemic lupus erythematosus

  2016cited by this paper
• Influence of geolocation and ethnicity on the phenotypic expression of primary Sjögren's syndrome at diagnosis in 8310 patients: a cross-sectional study from the Big Data Sjögren Project Consortium

  2016cited by this paper
• Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination

  2016cited by this paper
• Interleukin 33 is a guardian of barriers and a local alarmin

  2016cited by this paper
• Interleukin (IL)‐17‐producing pathogenic T lymphocytes co‐express CD20 and are depleted by rituximab in primary Sjögren's syndrome: a pilot study

  2016cited by this paper
• Blood and salivary-gland BAFF-driven B-cell hyperactivity is associated to rituximab inefficacy in primary Sjögren's syndrome.

  2016cited by this paper
• Genome-wide DNA methylation analysis in multiple tissues in primary Sjögren's syndrome reveals regulatory effects at interferon-induced genes

  2016cited by this paper
• Promoting Immune Regulation in Type 1 Diabetes Using Low-Dose Interleukin-2

  2016cited by this paper
• The Expression of BAFF Is Controlled by IRF Transcription Factors

  2016cited by this paper
• Regulator Versus Effector Paradigm: Interleukin-10 as Indicator of the Switching Response

  2016cited by this paper
• Distinct Functions of Autoantibodies Against Interferon in Systemic Lupus Erythematosus: A Comprehensive Analysis of Anticytokine Autoantibodies in Common Rheumatic Diseases

  2016cited by this paper
• Association of plasmacytoid dendritic cells with B cell infiltration in minor salivary glands in patients with Sjögren's syndrome

  2016cited by this paper
• Decreased expression of thymic stromal lymphopoietin in salivary glands of patients with primary Sjögren’s syndrome is associated with increased disease activity

  2016cited by this paper
• Neuromyelitis optica spectrum disorder complicated with Sjogren syndrome successfully treated with tocilizumab: A case report

  2016cited by this paper
• IL-2, IL-4, IFN-γ or TNF-α enhances BAFF-stimulated cell viability and survival by activating Erk1/2 and S6K1 pathways in neoplastic B-lymphoid cells.

  2016cited by this paper
• Interleukin 33: an innate alarm for adaptive responses beyond Th2 immunity–emerging roles in obesity, intestinal inflammation, and cancer

  2016cited by this paper
• Interleukin-17 Impairs Salivary Tight Junction Integrity in Sjögren’s Syndrome

  2016cited by this paper
• The IL33/ST2 axis in Sjogren syndrome in relation to disease activity.

  2016cited by this paper
• Mobilization of lymphatic endothelial precursor cells and lymphatic neovascularization in primary Sjögren's syndrome

  2016cited by this paper
• Potential involvement of IL-22 and IL-22-producing cells in the infl amed salivary glands of patients with Sjögren’s syndrome

  2016cited by this paper
• Increased IL-21 Expression Induces Granzyme B in Peripheral CD5+ B Cells as a Potential Counter-Regulatory Effect in Primary Sjögren's Syndrome

  2016cited by this paper
• Sjögren's syndrome: from pathogenesis to novel therapeutic targets.

  2016cited by this paper
• A comprehensive investigation on the distribution of circulating follicular T helper cells and B cell subsets in primary Sjögren's syndrome and systemic lupus erythematosus

  2016cited by this paper
• Interleukin-15 as a potential new target in Sjögren's syndrome-associated inflammation.

  2016cited by this paper
• Erratum to: Treating the Underlying Pathophysiology of Primary Sjögren Syndrome: Recent Advances and Future Prospects

  2016cited by this paper
• The Emerging Role of PI3K Inhibitors in the Treatment of Hematological Malignancies: Preclinical Data and Clinical Progress to Date

  2016cited by this paper
• Association of Increased Treg Cell Levels With Elevated Indoleamine 2,3‐Dioxygenase Activity and an Imbalanced Kynurenine Pathway in Interferon‐Positive Primary Sjögren's Syndrome

  2016cited by this paper
• Tocilizumab for refractory organising pneumonia associated with Sjögren's disease

  2015cited by this paper
• Cytokines as Therapeutic Targets in Rheumatoid Arthritis and Other Inflammatory Diseases

  2015cited by this paper
• Interleukin-2: Biology, Design and Application.

  2015cited by this paper
• High circulating levels of interleukin-18 in patients with primary Sjögren ’ s syndrome is associated with disease activity

  2015cited by this paper
• A pathogenetic role for IL-21 in primary Sjögren syndrome

  2015cited by this paper
• Update on the immunobiology of Sjögren's syndrome

  2015cited by this paper
• IL-22 regulates lymphoid chemokine production and assembly of tertiary lymphoid organs

  2015cited by this paper
• The role of IL-33 and mast cells in allergy and inflammation

  2015cited by this paper
• An in silico Approach Reveals Associations between Genetic and Epigenetic Factors within Regulatory Elements in B Cells from Primary Sjögren’s Syndrome Patients

  2015cited by this paper
• Efficacy and safety of belimumab given for 12 months in primary Sjögren's syndrome: the BELISS open-label phase II study.

  2015influential reference
• The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases

  2015cited by this paper
• Role of IL-38 and Its Related Cytokines in Inflammation

  2015cited by this paper
• IL-22 regulation of functional gene expression in salivary gland cells

  2015cited by this paper
• Overlap between differentially methylated DNA regions in blood B lymphocytes and genetic at-risk loci in primary Sjögren's syndrome

  2015cited by this paper
• T Regulatory and T Helper 17 Cells in Primary Sjögren's Syndrome: Facts and Perspectives

  2015influential reference
• Defective Selection of Thymic Regulatory T Cells Accompanies Autoimmunity and Pulmonary Infiltrates in Tcra-Deficient Mice Double Transgenic for Human La/Sjögren’s Syndrome-B and Human La-Specific TCR

  2015cited by this paper
• How are we treating our systemic patients with primary Sjögren syndrome? Analysis of 1120 patients.

  2015cited by this paper
• Association of IL-21 Cytokine With Severity of Primary Sjögren Syndrome Dry Eye

  2015cited by this paper
• Treatment with belimumab restores B cell subsets and their expression of B cell activating factor receptor in patients with primary Sjogren's syndrome.

  2015influential reference
• Interleukin-6 inhibits apoptosis of exocrine gland tissues under inflammatory conditions.

  2015cited by this paper
• Interleukin (IL)‐22 receptor 1 is over‐expressed in primary Sjogren's syndrome and Sjögren‐associated non‐Hodgkin lymphomas and is regulated by IL‐18

  2015cited by this paper
• Interleukin-10 paradox: A potent immunoregulatory cytokine that has been difficult to harness for immunotherapy.

  2015cited by this paper
• Interleukins (ILs), a fascinating family of cytokines. Part II: ILs from IL-20 to IL-38.

  2015cited by this paper
• Prediction of Sjögren's Syndrome Years Before Diagnosis and Identification of Patients With Early Onset and Severe Disease Course by Autoantibody Profiling

  2015cited by this paper
• Interleukin‐36α axis is modulated in patients with primary Sjögren's syndrome

  2015cited by this paper
• Efficacy and safety of belimumab in primary Sjögren's syndrome: results of the BELISS open-label phase II study.

  2015influential reference
• Targeting Interferons in Systemic Lupus Erythematosus: Current and Future Prospects

  2015cited by this paper
• Pitfalls for detecting interleukin-33 by ELISA in the serum of patients with primary Sjögren syndrome: comparison of different kits

  2015cited by this paper
• THU0392 Efficacy and Safety of Belimumab Given for 12 Months in Primary sjögren's Syndrome: The Beliss Open-Label Phase II Study

  2015influential reference
• the Clinical Efficacy and Safety of Baminercept, a Lymphotoxin-beta Receptor Fusion Protein, in Primary Sjögren's Syndrome: Results from a Randomized, Double-blind, Placebo-controlled Phase Ii Trial : abstract Number: 3203

  2015influential reference
• Type I and II interferon signatures in Sjogren's syndrome pathogenesis: Contributions in distinct clinical phenotypes and Sjogren's related lymphomagenesis.

  2015cited by this paper
• The role of innate and lymphoid IL-22-producing cells in the immunopathology of primary Sjögren's syndrome

  2014cited by this paper
• Th 17 cells play a critical role in the development of experimental Sjögren ’ s syndrome Q 1 ¶ Q 2 ¶

  2014influential reference
• Type I IFN signature in primary Sjögren’s syndrome patients

  2014cited by this paper
• Th17 cells play a critical role in the development of experimental Sjögren's syndrome

  2014influential reference
• Potential involvement of the IL-33–ST2 axis in the pathogenesis of primary Sjögren's syndrome

  2014cited by this paper
• Interleukins (ILs), a fascinating family of cytokines. Part I: ILs from IL-1 to IL-19.

  2014cited by this paper
• Are the B cells cast with the leading part in the Sjogren's syndrome scenario?

  2014cited by this paper
• Analysis of Th17-associated cytokines in tears of patients with dry eye syndrome

  2014cited by this paper
• Sequential therapy with belimumab followed by rituximab in Sjögren's syndrome associated with B-cell lymphoproliferation and overexpression of BAFF: evidence for long-term efficacy.

  2014cited by this paper
• Dendritic cells, T-cells and epithelial cells: a crucial interplay in immunopathology of primary Sjögren's syndrome

  2014cited by this paper
• Early events in Sjögren's Syndrome pathogenesis: the importance of innate immunity in disease initiation.

  2014cited by this paper
• The efficacy of novel B cell biologics as the future of SLE treatment: a review.

  2014cited by this paper
• Differentiation of follicular helper T cells by salivary gland epithelial cells in primary Sjögren's syndrome.

  2014influential reference
• IL17A impairs blood–testis barrier integrity and induces testicular inflammation

  2014cited by this paper
• B-cell hyperactivity in primary Sjögren's syndrome

  2014cited by this paper
• OP0079 Salivary Gland Epithelial Cells (SGECS) Promote the Differentiation of B Cells

  2013cited by this paper
• The Important Role of T Cells and Receptor Expression in Sjögren's Syndrome

  2013cited by this paper
• The interferon signature in autoimmune diseases

  2013cited by this paper
• Dendritic cells of the oral mucosa

  2013cited by this paper
• Primary Sjögren syndrome: an update on current pharmacotherapy options and future directions

  2013cited by this paper
• Advances in understanding the pathogenesis of primary Sjögren's syndrome

  2013cited by this paper
• Immunopathogenic mechanisms of systemic autoimmune disease.

  2013cited by this paper
• Targeting IL-1 in Sjögren's syndrome

  2013cited by this paper
• Topical administration of interleukin-1 receptor antagonist as a therapy for aqueous-deficient dry eye in autoimmune disease

  2013cited by this paper

• Diagnostic significance of salivary and glandular siglec-5 in Sjögren disease and non-Sjögren sicca

  2026cites this paper
• Primary Sjögren's Disease: a review of unmet need, outcome measures, therapeutic advances and health economic impacts. Lessons from the NEw Clinical Endpoints in primary Sjögren's Syndrome: an Interventional Trial based on stratifYing patients (NECESSITY) Innovative Health Initiative (IHI).

  2025cites this paper
• Self-Reported Non-Celiac Wheat Sensitivity and Other Food Sensitivities in Patients with Primary Sjögren’s Syndrome

  2025cites this paper
• Primary Sjögren syndrome specific B cells induced aberrant surface aggregation of B cell receptors (BCRs) and signalling

  2024cites this paper
• Tear cytokine levels in Sjogren’s syndrome-related dry eye disease compared with non-Sjogren’s syndrome-related dry eye disease patients: A meta-analysis

  2024cites this paper
• Activation of Janus kinase 2 contributes to the autoimmune pathology in the salivary glands of patients with Sjögren's syndrome

  2024cites this paper
• Involvement of Substance P (SP) and Its Related NK1 Receptor in Primary Sjögren’s Syndrome (pSS) Pathogenesis

  2023cites this paper
• Systematic review with meta-analysis: Efficacy and safety of biological treatment on salivary gland function in primary Sjögren’s syndrome

  2023cites this paper
• What exactly is the relationship between plasma cytokines and the clinical phenotype of primary sjögren's syndrome? a single-centre retrospective study.

  2023cites this paper
• The Role of Regulatory T Cells in the Onset and Progression of Primary Sjögren’s Syndrome

  2023cites this paper
• The role of epithelial cells in the immunopathogenesis of Sjögren's syndrome.

  2023cites this paper
• Sirolimus therapy restores the PD-1+ICOS+Tfh:CD45RA-Foxp3high activated Tfr cell balance in primary Sjögren's syndrome.

  2022cites this paper
• Altered white matter structural connectivity in primary Sjögren’s syndrome: a link-based analysis

  2022cites this paper
• Innate Immune Dysregulation in Sjögren’s Syndrome

  2021cites this paper
• Lycium barbarum Polysaccharide Ameliorates Sjögren's Syndrome in a Murine Model.

  2021cites this paper
• Primary Sjögren’s Syndrome: A Retrospective Cohort Study of Burden of Illness in Sweden

  2021cites this paper
• Biological Therapy in Primary Sjögren's Syndrome: Effect on Salivary Gland Function and Inflammation

  2021cites this paper
• An update of targeted therapeutic options for primary Sjögren syndrome: current status and future development

  2021cites this paper
• The Clinical and Immunological Activity Depending on the Presence of Interferon γ in Primary Sjögren’s Syndrome—A Pilot Study

  2021cites this paper
• Hydroxychloroquine in rheumatic autoimmune disorders and beyond

  2020cites this paper
• Primary Sjogren Syndrome: Focus on Innate Immune Cells and Inflammation

  2020cites this paper
• Innate Immunity and Biological Therapies for the Treatment of Sjögren’s Syndrome

  2020influential citation
• Cytokine profiles and clinical characteristics in primary Sjögren´s syndrome patient groups

  2020cites this paper
• EULAR recommendations for the management of Sjögren’s syndrome with topical and systemic therapies

  2019cites this paper
• MicroRNA-130a Contributes to Type-2 Classical DC-activation in Sjögren's Syndrome by Targeting Mitogen- and Stress-Activated Protein Kinase-1

  2019cites this paper
• Clinical significance of serum bilirubin in primary Sjögren syndrome patients

  2019cites this paper
• Effectiveness and safety of abatacept for the treatment of patients with primary Sjögren’s syndrome

  2019cites this paper
• Innate and Adaptive Cell Populations Driving Inflammation in Dry Eye Disease

  2018cites this paper
• Kierunki w etiopatognezie pierwotnego zespołu Sjögrena

  2018cites this paper
• Expression of interleukin‐17 in primary Sjögren's syndrome and the correlation with disease severity: A systematic review and meta‐analysis

  2018cites this paper